Evidence map›Paper›PMID 40033039›Full record

ArticleScientific reports2025

Synthesis, physicochemical characterization and biological activity of novel pyrrole flavones.

Stepan Sysak, Barbara Wicher, Malgorzata Kucinska, Paulina Kobylka, Dariusz T Mlynarczyk, Roman Lesyk, Ewa Tykarska, Marek Murias, Tomasz Goslinski, Wojciech Szczolko

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Stepan SysakChair and Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Rokietnicka 3, 60-806, Poznań, Poland.
Barbara WicherChair and Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Rokietnicka 3, 60-806, Poznań, Poland.
Malgorzata KucinskaChair and Department of Toxicology, Poznan University of Medical Sciences, Rokietnicka 3, 60-806, Poznań, Poland.
Paulina KobylkaDoctoral School, Poznan University of Medical Sciences, Bukowska 70, 60-812, Poznań, Poland.
Dariusz T MlynarczykChair and Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Rokietnicka 3, 60-806, Poznań, Poland.
Roman LesykDepartment of Biotechnology and Cell Biology, Medical College, University of Information Technology and Management in Rzeszów, Sucharskiego 2, 35-225, Rzeszów, Poland.
Ewa TykarskaChair and Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Rokietnicka 3, 60-806, Poznań, Poland.
Marek MuriasChair and Department of Toxicology, Poznan University of Medical Sciences, Rokietnicka 3, 60-806, Poznań, Poland.
Tomasz GoslinskiChair and Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Rokietnicka 3, 60-806, Poznań, Poland. tomasz.goslinski@ump.edu.pl.
Wojciech SzczolkoChair and Department of Chemical Technology of Drugs, Poznan University of Medical Sciences, Rokietnicka 3, 60-806, Poznań, Poland. wszczolko@ump.edu.pl.

Funding

Narodowe Centrum Nauki 2019/35/B/NZ7/01165
6 · The paper itself

Abstract

Cancer remains one of the most significant health issues worldwide. By designing compounds with anticancer activity characterized by high selectivity towards cancer cells, medicinal chemistry focuses on the protection of healthy cells and tissues. In this study, we present the hybrid pharmacophore approach, which afforded a series of new pyrrole flavones. The synthetic strategy was based on the Paal-Knorr pyrrole synthesis, starting from aminoflavones through their condensation with 1,4-diketones and leading to 6- and 7-(pyrrol-1-yl) flavones. The isolated products underwent characterization using NMR and UV-VIS spectroscopy, mass spectrometry, TGA, DSC, and Microtox analyses. For all pyrrole flavones, single crystals were obtained and subjected to X-ray diffraction experiments. Their cytotoxic activity was assessed on two human bladder cancer cell lines (5637 and HT-1376) and one non-cancerous (MRC-5) cell line, showing the potential as anticancer agents. Flavone derivative with the 6-(2-methyl-5-phenylpyrrol-1-yl) moiety was active in the MTT assay towards 5637 and HT-1376 cancer cells after 24 h of incubation with IC

Indexed as

Antineoplastic AgentsFlavonesPyrrolesCell Line, TumorCell ProliferationCell SurvivalDrug Screening Assays, AntitumorHumansStructure-Activity RelationshipAntineoplastic AgentsFlavonesPyrrolesAnticancer activityBladder cancer cell lineFlavonoidsPaal–Knorr synthesisPyrroleX-ray structure

Identifiers

PMID40033039
PMCPMC11876692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.